Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Collier · SciRah

Researcher profile · Semantic Scholar

A. Collier

Share profile

A. Collier — researcher profile on SciRah

h-index: 3
Works: 13
Citations: 58

Most-cited papers

CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape
Nayan Chaudhary, A. Chibly, A. Collier, J. Martinalbo +5 more
2024npj Breast Cancer32 citations Open access
Semantic Scholar
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
S. Chandarlapaty, M. Dickler, J. A. Perez Fidalgo, R. Villanueva-Vázquez +12 more
2023Clinical Cancer Research8 citations Open access
Semantic Scholar
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).
S. Swain, C. Barrios, R. Basho, G. Curigliano +12 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer
A. Collier, S. Hilz, A. Chibly, Chunzhe Duan +10 more
2026Nature Communications3 citations
Semantic Scholar
Abstract PS1-12-11: Giredestrant immobilizes the Estrogen Receptor to potently suppress ER-active breast cancers
J. Guan, W. Zhou, J. Liang, A. Collier +3 more
2026Clinical Cancer Research2 citations
Semantic Scholar
Giredestrant (G) with atezolizumab (ATEZO), and/or abemaciclib (ABEMA) in patients (pts) with ER+/HER2– locally advanced/metastatic breast cancer (LA/mBC): Interim analysis (IA) from the phase I/II MORPHEUS Breast Cancer study.
Mafalda Oliveira, A. Sonnenblick, S. Stemmer, M. Gion +14 more
2025Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Abstract PS17-07: Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer
H. Rugo, M. Gion, C. Hernando, K. Jung +11 more
2024Cancer Research2 citations
Semantic Scholar
Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC).
S. Wander, S. Stemmer, H. Rugo, Seock-Ah Im +9 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract PS2-11-28: Gdc-4198, a next-generation CDK4/2 inhibitor, induces durable cell cycle arrest and overcomes CDK2-driven adaptation to CDK4 inhibition
M. Hafner, S. Vartanian, G. Luca, N. Kosaisawe +15 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).
A. Collier, Mariana Chavez Mac Gregor, S. Hilz, A. Bardia +6 more
2023Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract 2606: A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
A. Collier, Jonathon Beagan, Travis A. Clark, Kristian Cibulskis +11 more
2026Cancer Research0 citations
Semantic Scholar
Abstract 1910: GDC-4198, a next-generation CDK4/2 inhibitor, induces durable cell cycle arrest and shows combination benefit with giredestrant.
M. Hafner, Steffan Vartanian, Luca Gerosa, N. Kosaisawe +15 more
2026Cancer Research0 citations
Semantic Scholar
Abstract PO1-05-07: Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer
A. Collier, A. Bardia, J. Sohn, E. Lim +5 more
2024Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Perez-Moreno×6
Invite
P. Perez-Moreno — researcher profile on SciRah
M. Hafner×4
Invite
M. Hafner — researcher profile on SciRah
A. Bardia×4
Invite
A. Bardia — researcher profile on SciRah
R. Schwab×4
Invite
R. Schwab — researcher profile on SciRah

×3

Invite

J. Martinalbo — researcher profile on SciRah

Heather M. Moore×3

Invite

Heather M. Moore — researcher profile on SciRah

Invite

C. Metcalfe — researcher profile on SciRah

Invite

H. Rugo — researcher profile on SciRah

Invite

H. Ngo — researcher profile on SciRah

Invite

Jing Zhu — researcher profile on SciRah

Invite

A. Chibly — researcher profile on SciRah

Invite

H. Moore — researcher profile on SciRah